Monoklonal Antikor (Hedef Ajan) Kullanan Kanser Hastalarının Semptom Sıklıkları Ve Yaşam Kalitelerinin İncelenmesi

Amaç: Monoklonal antikorlar (hedef ajan) son yıllarda pekçok hastalığın tedavisinde kullanılmaktadır. Kanserli hastaların tedavisinde de yaygın olarak kullanılmaya başlanılan bu ilaçlar başarılı sonuçlar göstermektedir. Bu çalışmanın amacı monoklonal antikor kullanan kanserli hastaların semptom sıkları ve yaşam kalitelerinin incelenmesidir. Yöntem: 28 Şubat- 31 Mayıs 2017 tarihleri arasında kemoterapi ünitesine başvuran, 18 yaşından büyük olan, 103 hasta ile görüşülmüştür. Hasta Soru Formu, Memorial Semptom Değerlendirme Skalası (MSAS), ve Yaşam Kalitesi İndeksi –Kanser Versiyonu-III (Quality of Life Index–Cancer Version-III (QOL-CV) ) kullanılmıştır. Bulgular: Katılımcıların %70.9’u kadın, %30.1’i ilkokul mezunu, %74.8’i evli, %85.4’ü çalışmayan bireylerdir. Hastaların total MSAS puanı 0.69, QOL toplam ölçek puanı 22.15 olarak hesaplanmıştır. MSAS- Fiziksel alt boyut puanı ile eğitim ve monoklonal çeşitleri arasında ilişki saptanmıştır. QOL toplam ve alt boyutlarının pek çok bağımsz değişken ile arasında anlamlı bir ilişki bulunmuştur. Sonuç: Monoklonal antikor kullanan kanser hastalarının semptomlarla ilgili sıklık, şiddet ve sıkıntıları arttığında yaşam kalitelerinde nispeten olumsuz değişiklikler görülmektedir.

Anahtar Kelimeler:

monoklonal antikor, kanser, yaşam kalitesi, semptom

Examination of Symptom Frequency and Quality of Life of Cancer Patients Using Monoclonal Antibody (Target Agent)

Aim : Monoclonal antibodies (target agent) have been used in the treatment of many diseases in recent years. These drugs, which have been widely used in the treatment of cancer patients, show successful results. The aim of this study is to examine the symptom frequencies and quality of life of cancer patients using monoclonal antibodies. Method: Between February 28 and May 31, 2017, 103 patients, aged 18 years or older, who were referred to the chemotherapy unit, were interviewed. Patient Questionnaire, Memorial Symptom Assessment Scale (MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV) were used. Findings: 70.9% of the participants were women, 30.1% were primary school graduates, 74.8% were married and 85.4% were not working. Total MSAS score of the patients was calculated as 0.69, QOL total scale score was 22.15. MSAS- Physical subscale score and education and monoclonal varieties. QOL total and sub-dimensions were found to be significantly correlated with many independent variables. Result: Cancer patients using monoclonal antibodies have relatively negative changes in their quality of life when the incidence, severity, and frequency of symptoms increase.: Monoclonal antibodies (target agent) have been used in the treatment of many diseases in recent years. These drugs, which have been widely used in the treatment of cancer patients, show successful results. The aim of this study is to determine the frequency of symptoms and the quality of life of cancer patients using monoclonal antibodies. Method: Between February 28 and May 31, 2017, 103 patients, aged 18 years or older, who were referred to the chemotherapy unit, were interviewed. Patient Questionnaire Memorial Symptom Assessment Scale (MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV) were used. Conclusion: 70.9% of the participants were women, 30.1% were primary school graduates, 74.8% were married and 85.4% were not working. Total MSAS score of the patients was calculated as 0.69, QOL total scale score was 22.15. MSAS- Physical subscale score and education and monoclonal varieties. QOL total and sub-dimensions were found to be significantly correlated with many independent variables. Result: Cancer patients using monoclonal antibodies have relatively negative changes in their quality of life when the incidence, severity, and frequency of symptoms increase.

Keywords:

monoclonal antibody, cancer, quality of life, symptom,

PDF

___

1. Fadıloğlu Ç, Tokem Y, Özçelik H. Biyolojik ajanların kullanımında hemşirenin sorumlulukları. Türk onkoloji dergisi 2008;23(1):45-53.
2. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Macmillan Publishers Limited. All rights reserved, www.nature.com/reviews/cancer;. 2012;April, V(12): 278-286.
3. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373: 1033–40.
4. Lenz HJ. Management and preparedness for ınfusionand hypersensitivity reactions. TheOncologist2007;12:601–609 www.TheOncologist.com
5. Akın S, Can G, Aydıner A, Özdilli K, Durna Z. Quality of life symptom experience and distress of lung cancer patients undergoing chemotherapy. European Journal of Oncology Nursing. 2010;14: 400–409.
6. Sammarco A, Konecny LM. Quality of life, social support, and uncertainty among latina and caucasian breast cancer survivors: A comparative study. Oncology Nursing Forum 2010; Vol. 37 (1): 93-99.
7. Yıldırım Y, Tokem Y, Bozkurt N, Fadiloglu Ç, Uyar M, Uslu R. Reliability and validity of the Turkish version of Memorial Symptom Assessment Scale in cancer patients. Asian Pacific J Cancer Prev,2011; 12, 3389-3396 .
8. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton N, Scher H. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress . European Journal of Cancer, 1994;Vol. 30A, No. 9,pp. 1326-1336.
9. Can G, Durna Z, Aydıner A. The validity and reliability of the Turkish version of the Quality Of Life Index. European Journal of Oncology Nursing. 2010;14: 316-321.
10. Salonen P, Kellokumpu-Lehtinen PR, Tarkka MT, Koivisto AM, Kaunonen M. Changes in quality of life in patients with breast cancer. Journal of Clinical Nursing, 2010; 20, 255–266.
11. Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DFT, Reynolds JL, Ansell CM, Oh EY, Daehler MA, Levin RD et al. The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer 2011; 11:193.
12. Aksakoğlu G. Veri çözümlemenin temeli. Sağlıkta araştırma ve çözümleme. İkinci basım. 2006;161-180.
13. Çalışkan T, Duran S, Karadaş A, Ergün S.,Tekir Ö. Kanser hastalarının yaşam kalitesi ve sosyal destek düzeylerinin değerlendirilmesi. KÜ Tıp Fak Dergisi. 2015; 17(1): 27-36.
14. Sarenmalm EK, Öhlen J, Jonsson T, Gaston-Johanson F. Coping with recurrent breast cancer: predictors of distressing symptoms and health-related Quality of life. Journal of Pain and Symptom Management. 2007;Vo: 34 (1):24-39.
15. Sert F, Özsaran Z, Eser E, Alanyalı S, Haydaroğlu A, Aras A. Meme kanseri tanılı olgularda uygulanan tedavinin yaşam kalitesine etkisinin değerlendirilmesi. J Breast Health 2013; 9: 57-63.
16. Salonen P, kellokumpu-Lehtınen PL, Huhtala H, Kaunonen M. The quality of life and social support in signiﬁcant others of patients with breast cancer – a longitudinal study. European Journal of Cancer Care, 2014, 23, 274–283.
17. Özçınar B, Güler SA, Özmen V, Güllüoğlu BM, Kocaman N, Özkan M, Sarıçam G, Müslümanoğlu ME, İğciA, Keçer M. Meme kanserinde lokal/bölgesel tedavi sonrası görülen komplikasyonlar ve bunların hasta yaşam kalitesi üzerine etkileri. The Journal of Breast Health 2010;Vol: 6 (1): 9-16.18.
18. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. European Journal of Pharmacology. 2009; 625: 41–54.
19. Martín M, Esteva FJ, Alba,E, Khandherıa B, Pérez-Isla L, García-Sáenz JÁ, Márquez A, Sengupta P, Zamoranoe J. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. The Oncologist 2009;14:1–11 www.TheOncologist.com
20. Altıparmak S, Fadıloğlu Ç, Gürsoy ŞT, Altıparmak O. Kemoterapi tedavisi alan akciğer kanserli hastalarda öz bakım gücü ve yaşam kalitesi ilişkisi. Ege Tıp Dergisi / Ege Journal of Medicine. 2011; 50 (2): 95-102.
21. Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacology & Therapeutics.2013; 138: 452-469.
22. Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with her2-positive metastatic breast cancer: data from three clinical trials. Clinical Breast Cancer August 2010; 288-293.